Goldman Sachs Maintains Neutral on Arrowhead Pharma, Raises Price Target to $85

Benzinga · 5d ago
Goldman Sachs analyst Andrea Tan maintains Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and raises the price target from $50 to $85.